InvestorsHub Logo
Followers 46
Posts 4449
Boards Moderated 0
Alias Born 07/26/2010

Re: RNsidersbuying post# 448

Thursday, 05/02/2019 10:36:03 AM

Thursday, May 02, 2019 10:36:03 AM

Post# of 561
Showing $8.83 netcash remaining after the executives raided-the-till heavily this quarter. Still my favorite play - added at 8.02 at the open - many catalysts working here:

Expected Milestones

Present final results for all subjects from the MarzAA Phase 2 open-label SQ efficacy trial at the ISTH meeting in July 2019; initiate a MarzAA Phase 1 pharmacokinetic and pharmacodynamic study in Q2 2019 with final data read out in Q4 2019; and request an End of Phase 2 meeting with the FDA by the end of 2019.

Complete the DalcA Phase 2b open-label SQ long-term dosing study, with final data readout in Q4 2019.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CBIO News